8 results on '"Justin Jiang"'
Search Results
2. 3130 Evaluation of the delivery of specialist first seizure care in Australia
- Author
-
David Vaughan, Emma Foster, Patrick Carney, Wendyl D'Souza, and Justin Jiang
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Published
- 2024
- Full Text
- View/download PDF
3. Improvement in survival of acute myeloid leukemia and myelodysplastic syndrome patients following allogeneic transplant: a long-term institutional experience
- Author
-
Audrey M. Sigmund, Justin Jiang, Qiuhong Zhao, Patrick Elder, Don M. Benson, Sumithira Vasu, Samantha Jaglowski, Alice S. Mims, Hannah Choe, Karilyn Larkin, Jonathan E. Brammer, Sarah A. Wall, Nicole Grieselhuber, William Basem, Sam Penza, Yvonne A. Efebera, and Nidhi Sharma
- Subjects
acute myeloid leukemia ,allogenic transplantation ,overall survival ,progression-free survival ,graft-versus-host disease ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundAllogeneic stem cell transplant (allo-SCT) plays a key role in the treatment of patients with both acute myeloid leukemia (AML) and myelodysplastic (MDS). Outcomes of allo-SCT have improved with optimization of transplant practices. We sought to evaluate trends in survival in AML and MDS patients undergoing allo-SCT at our institution from 1984 to 2018.MethodsA retrospective analysis of 900 consecutive AML and MDS patients undergoing allo-SCT was performed. Patients were divided by year of transplant for analysis. Primary endpoints were progression free survival (PFS) and overall survival (OS). Secondary endpoints included non-relapse mortality (NRM), graft-versus-host disease (GVHD), GVHD-free relapse free survival (GRFS), and transplant complications.ResultsWe found a significant improvement in survival from 1984 to 2018 with 5-year PFS and OS improving from 17% to 49% and 17% to 53%, respectively (statistically significant difference since 2004; p
- Published
- 2023
- Full Text
- View/download PDF
4. Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant
- Author
-
Audrey M. Sigmund, Qiuhong Zhao, Justin Jiang, Patrick Elder, Don M. Benson, Ashley Rosko, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Sumithira Vasu, Samantha Jaglowski, Alice Mims, Hannah Choe, Karilyn Larkin, Jonathan Brammer, Sarah Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Yvonne A. Efebera, and Nidhi Sharma
- Subjects
race ,geographic location of residence ,allogeneic transplant ,health disparities ,GvHD ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundAllogeneic hematopoietic stem cell transplant (allo-HCT) is a potential curative therapy for a variety of hematologic disorders. However, it requires highly specialized care that is only available at select centers across the country. Thus, minority populations are at risk for healthcare disparities in access to and outcomes of allo-HCT. Our study aimed to assess the impact of race and location of residence on outcomes of allo-HCT.MethodsWe performed a retrospective analysis of all patients who underwent allo-HCT at the Ohio State University from 1984 to 2018. Patients were divided by race (Caucasian, African American, and other) and grouped by zip code into rural, suburban, and urban groups. Primary endpoints included progression-free survival (PFS) and overall survival (OS).ResultsOf the 1,943 patients included in the study, 94.3% self-identified as Caucasian, 4.6% African American, and 1.1% other. In total, 63.4% lived in rural areas, 22.9% suburban, and 13.8% urban. There was no significant difference in OS or PFS by race (p = 0.15, 0.21) or place of residence (p = 0.39, 0.17). In addition, no difference in nonrelapse mortality, acute and chronic graft-versus-host disease (GVHD), and GVHD-free relapse-free survival (GRFS) was seen among the race or place of residence.ConclusionOur study suggests that when appropriate access to HCT is given, there is no difference in outcomes based on race, ethnicity or place of primary residence. Further research is needed to further evaluate barriers for these patients to undergo transplant and help mitigate these barriers.
- Published
- 2022
- Full Text
- View/download PDF
5. Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation
- Author
-
Karilyn Larkin, Audrey M. Sigmund, Alice S. Mims, Patrick Elder, Nicole Grieselhuber, Ayman Saad, Yvonne A. Efebera, Qiuhong Zhao, Srinivas Devarakonda, Sarah A Wall, Ashley E. Rosko, Don M. Benson, Muhammad Salman Faisal, Justin Jiang, Sumithira Vasu, Hannah Choe, Nidhi Sharma, Naresh Bumma, Abdullah Khan, Jonathan E. Brammer, Sam Penza, Samantha Jaglowski, and Maria Chaudhry
- Subjects
medicine.medical_specialty ,bone marrow ,Cyclophosphamide ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,haploidentical transplantation ,business.industry ,Incidence (epidemiology) ,allogenic transplantation ,General Medicine ,peripheral blood ,Confidence interval ,Peripheral blood ,Transplantation ,medicine.anatomical_structure ,surgical procedures, operative ,030220 oncology & carcinogenesis ,Cohort ,Medicine ,Bone marrow ,Stem cell ,business ,030215 immunology ,medicine.drug - Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical (haplo) donor has emerged as a suitable alternative in the absence of a matched donor. However, haplo-HCT patients have a higher risk of graft-versus-host disease (GVHD). Hence, bone marrow (BM) stem cell source and post-transplant cyclophosphamide (PTCy) have been routinely used to help mitigate this. Due to ease of collection, peripheral blood (PB) stem cells are increasingly being considered for haplo-HCT. We retrospectively analyzed 74 patients (42 BM and 32 PB) who underwent haplo-HCT at Ohio State University from 2009 to 2018. Median age at transplant was 60 years (yrs) for BM and 54 yrs for PB, (p = 0.45). There was no difference in OS (p = 0.13) and NRM (p = 0.75) as well as PFS (p = 0.10) or GRFS (p = 0.90) between the groups. The BM cohort showed a 3-year OS rate of 63% (95% confidence interval (CI): 46–76), and 3-year PFS of 49% (95% CI: 33–63). For the PB group, 3-year OS and PFS were 78% (95% CI: 59–89) and 68% (95% CI: 49–82), respectively. There were no differences in the incidence of acute GVHD (grade II-IV) (p = 0.31) and chronic GVHD (p = 0.18). Patients receiving BM had a significantly higher risk for relapse with relapse rates by 2 years at 36% (95% CI: 22–50) vs. 16% (95% CI: 6–31) for PB (p = 0.03). The findings from this study suggest that PB is an excellent alternative to BM for haplo-HCT.
- Published
- 2021
6. A Hybridde novoAssembly of the Sea Pansy (Renilla muelleri) Genome
- Author
-
Estefanía Rodríguez, Catherine S. McFadden, Andrea M. Quattrini, Justin Jiang, Joseph F. Ryan, and Warren R. Francis
- Subjects
0106 biological sciences ,Renilla ,food.ingredient ,Octocorallia ,Gene prediction ,Sequence assembly ,Health Informatics ,Genomics ,Nematostella ,Augustus ,Data Note ,01 natural sciences ,Genome ,octocoral ,03 medical and health sciences ,food ,hybrid assembly ,Anthozoa ,Animals ,030304 developmental biology ,PacBio ,Comparative genomics ,0303 health sciences ,biology ,Computational Biology ,High-Throughput Nucleotide Sequencing ,Starlet sea anemone ,Molecular Sequence Annotation ,biology.organism_classification ,Computer Science Applications ,MaSuRCA ,Evolutionary biology ,gene prediction ,010606 plant biology & botany - Abstract
BackgroundOver 3,000 species of octocorals (Cnidaria, Anthozoa) inhabit an expansive range of environments, from shallow tropical seas to the deep-ocean floor. They are important foundation species that create coral “forests” which provide unique niches and three-dimensional living space for other organisms. The octocoral genusRenillainhabits sandy, continental shelves in the subtropical and tropical Atlantic and eastern Pacific Oceans.Renillais especially interesting because it produces secondary metabolites for defense, exhibits bioluminescence, and produces a luciferase that is widely used in dual-reporter assays in molecular biology. Although several cnidarian genomes are currently available, the majority are from hexacorals. Here, we present ade novoassembly of theR. muellerigenome, making this the first complete draft genome from an octocoral.FindingsWe generated a hybridde novoassembly using the Maryland Super-Read Celera Assembler v.3.2.6 (MaSuRCA). The final assembly included 4,825 scaffolds and a haploid genome size of 172 Mb. A BUSCO assessment found 88% of metazoan orthologs present in the genome. An Augustusab initiogene prediction found 23,660 genes, of which 66% (15,635) had detectable similarity to annotated genes from the starlet sea anemone,Nematostella vectensis,or to the Uniprot database. Although theR. muellerigenome is smaller (172 Mb) than other publicly available, hexacoral genomes (256-448 Mb), theR. muellerigenome is similar to the hexacoral genomes in terms of the number of complete metazoan BUSCOs and predicted gene models.ConclusionsTheR. muellerihybrid genome provides a novel resource for researchers to investigate the evolution of genes and gene families within Octocorallia and more widely across Anthozoa. It will be a key resource for future comparative genomics with other corals and for understanding the genomic basis of coral diversity.
- Published
- 2018
- Full Text
- View/download PDF
7. GlcNAc Conjugated Atorvastatin with Enhanced Water Solubility and Cellular Internalization
- Author
-
Justin Jiang, Wenqing Li, Xiaofang Chen, Xiao Luo, Xinfu Zhang, Chunxi Zeng, Bin Li, Yizhou Dong, and Weiyu Zhao
- Subjects
0301 basic medicine ,media_common.quotation_subject ,Atorvastatin ,Biomedical Engineering ,Pharmaceutical Science ,Bioengineering ,Conjugated system ,Reductase ,01 natural sciences ,Article ,Acetylglucosamine ,Cell Line ,03 medical and health sciences ,Structure-Activity Relationship ,medicine ,Structure–activity relationship ,Humans ,Solubility ,Internalization ,media_common ,Pharmacology ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Water ,Biological Transport ,Ligand (biochemistry) ,0104 chemical sciences ,030104 developmental biology ,Biochemistry ,Drug delivery ,Biotechnology ,medicine.drug - Abstract
Targeting ligands facilitate cell specific drug delivery and improve pharmaceutical properties. Herein, we designed two ligand drug conjugates by conjugating GlcNAc (N-acetylglucosamine) with atorvastatin. These two conjugates, termed G-AT and G-K-AT, exhibited enhanced water solubility and cellular uptake. Moreover, both G-AT and G-K-AT were able to release atorvastatin and consequently achieve significant inhibition against 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase.
- Published
- 2017
8. GlcNAc Conjugated Atorvastatin with Enhanced Water Solubility and Cellular Internalization.
- Author
-
Xinfu Zhang, Xiaofang Chen, Weiyu Zhao, Chunxi Zeng, Xiao Luo, Wenqing Li, Bin Li, Justin Jiang, and Yizhou Dong
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.